Net income
−$619.9K
−1849.3% vs same quarter last year
EPS, diluted
−$0.01
Operating cash flow
−$349.8K
−377.9% vs same quarter last year
Operating income
−$654.6K
−192.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$2.1M |
| FY24 | - | −$2.4M |
| FY23 | - | −$4.5M |
| FY22 | - | −$2.5M |
| FY21 | - | −$4M |
| FY20 | - | −$2.5M |
| FY19 | - | −$1.9M |
| FY18 | - | −$296.4K |
| FY17 | $191.1K | −$318.4K |
| FY16 | $246.5K | −$696.8K |
| FY15 | $255.8K | −$2.1M |
| FY14 | $275.6K | −$1.3M |
| FY13 | $417.3K | −$1.8M |
| FY12 | $312.9K | −$2.3M |
| FY11 | $76.3K | −$4.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | 45.6% | −162.5% | −166.6% |
| FY16 | 60.9% | −272.3% | −282.7% |
| FY15 | 47% | −817.9% | −820.9% |
| FY14 | 39.8% | −464.7% | −488.7% |
| FY13 | 52.7% | −472.6% | −426.2% |
| FY12 | 61% | −731.8% | −732.9% |
| FY11 | 75% | −5803.6% | −5809.3% |
- Bioxytran
- Healthcare median
Show the numbers
| Year | Bioxytran | Healthcare median |
|---|---|---|
| FY25 | - | −40.6% |
| FY24 | - | −60.7% |
| FY23 | - | −97.1% |
| FY22 | - | −128.5% |
| FY21 | - | −129.2% |
| FY20 | - | −136.5% |
| FY19 | - | −133.7% |
| FY18 | - | −173.4% |
| FY17 | −166.6% | −176.7% |
| FY16 | −282.7% | −164.8% |
| FY15 | −820.9% | −183.4% |
| FY14 | −488.7% | −133% |
| FY13 | −426.2% | −88.5% |
| FY12 | −732.9% | −87.4% |
| FY11 | −5809.3% | −76.3% |
News
No stories filed under Bioxytran yet - coverage appears here as the news feed clusters it.